Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

Posters

Search Title by author or title

Use of a new double-segment intracorneal ring for the treatment of inferior keratoconus

Poster Details

First Author: F. Sanchez Leon MEXICO

Co Author(s):    S. Sanoja Sarabia                    

Abstract Details

Purpose:

To analyze the efficay, safety and effect on corneal topography regularity after a new double intracorneal ring segment implantation for the treatment of keratoconus and LASIK ectasia.

Setting:

Novavision Laser Center, Mexico City

Methods:

A group of 6 cases where a new double ring Intracorneal Segment (2 segments connected by several bridges and with ideal curvature) was implanted for the treatment of keratoconus and LASIK ectasia. Femtosecond laser was used to carve the channel Inn Diameter of 4.7 mm, Outer Diam of 6.8 m. UCVA, BCVC, corneal topography, corneal tomography and wavefront analysis was evaluated. Surgical complications were also analyzed.

Results:

A total of 6 cases were included. Mean UCVA Preop 1.00 Log, improved mean UCVA postop 0.40 Log. Mean preop BCVA 0.48 Log, improved mean postop BCVA 0.20 Log. Mean preop SE -4.50 Dt, improve to mean postop SE -1.25 Dt. Cornel topography and tomography shown regularity improvement in all cases. Wavefront analysis shown a mean reduction in HOA, and horizontal coma shown a mean reduction from -1.312 microns, to -0.485 microns. No complications were observed.

Conclusions:

New double arc segment based on ideal keratometry implantated in patients with keratoconus and LASIK ectasia shown improvement on UCVA, BCVA, refraction and corneal topography regularity. This new generation of intracorneal rings shown to be efficient and safe for the treatment of keratectasia.

Financial Disclosure:

One or more of the authors research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented

Back to Poster listing